The authors retract this Letter on the basis that the two most potent D1R agonists described in this Letter (compounds 19 and 24) had been previously discovered at Pfizer and chemical structures reported in two of their published patent applications. Therefore, these two compounds should not have been highlighted or described as novel compounds and should have been referenced to the prior patent literature.1,2 Citation correction alone would not sufficiently address potential intellectual property concerns, and therefore, this Letter is being retracted. The authors consider that all scientific results described in this Letter are valid and plan to republish the findings in a corrected report.
The original Letter was published on April 5, 2019, and retracted on May 17, 2022.
References
- Coe J. W.; Allen J. A.; Davoren J. E.; Dounay A. B.; Efremov I. V.; Gray D. L.; Guilmette E. R.; Harris A. R.; Helal C. J.; Henderson J. L.; Mente S. R.; Nason D. M.; O’Neil S. V.; Subramanyam C.; Xu W.. Heteroaromatic Compounds and Their Use as Dopamine D1 Ligands. WO2014/072881, 2014.
- Brodney M. A.; Davoren J. E.; Dounay A. B.; Efremov I. V.; Gray D. L.; Green M. E.; Henderson J. L.; Lee C.; Mente S. R.; O’Neil S. V.; Zhang L.. Heteroaromatic Compounds and Their Use as Dopamine D1 Ligands. WO2014/207601, 2014.